Top Suppliers:I want be here


81403-80-7

81403-80-7 structure
81403-80-7 structure
  • Name: Alfuzosin
  • Chemical Name: alfuzosin
  • CAS Number: 81403-80-7
  • Molecular Formula: C19H27N5O4
  • Molecular Weight: 389.449
  • Catalog: API Circulatory system medication Antihypertensive drug
  • Create Date: 2018-03-16 08:00:00
  • Modify Date: 2024-01-02 20:49:07
  • Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).Target: α1 adrenergic receptorAlfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia.Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component to their obstruction. In addition, alfuzosin offers an alternative to prostatectomy (the current 'gold standard') in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery.

Name alfuzosin
Synonyms Alfuzosin
Xatral
Urion
ALFUZOCIN
SL 77499-10
ALFUZOSIN HYDROCLORIDE
2-furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-
MFCD00865792
ALFUZOSINE
Alfuzosion
Alfoten
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
N-{3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl}tetrahydro-2-furancarboxamide
Afluzosin
Description Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).Target: α1 adrenergic receptorAlfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia.Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component to their obstruction. In addition, alfuzosin offers an alternative to prostatectomy (the current 'gold standard') in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery.
Related Catalog
References

[1]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29.

Density 1.3±0.1 g/cm3
Molecular Formula C19H27N5O4
Molecular Weight 389.449
Exact Mass 389.206299
PSA 111.83000
LogP -1.00
Index of Refraction 1.621
Storage condition 2-8℃
Risk Phrases R20/21/22
Safety Phrases S36/37

~80%

81403-80-7 structure

81403-80-7

Literature: UNICHEM LABORATORIES LIMITED Patent: WO2008/84493 A2, 2008 ; Location in patent: Page/Page column 9 ;

~71%

81403-80-7 structure

81403-80-7

Literature: AUROBINDO PHARMA LIMITED Patent: WO2007/74364 A1, 2007 ; Location in patent: Page/Page column 9 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2010/10058 A1, ; Page/Page column 14 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2006/90268 A2, ; Page/Page column 28; 30-31 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2006/30449 A1, ; Page/Page column 5-6 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2007/74364 A1, ; Page/Page column 8 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2008/15525 A2, ; Page/Page column 7; 10-11 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2009/7987 A1, ; Page/Page column 11 ;

~%

81403-80-7 structure

81403-80-7

Literature: WO2006/90268 A2, ; Page/Page column 30 ;